Patents Examined by Robert M. Kelly
  • Branched receptor binding multi-subunit protein complexes for use in bacterial delivery vehicles
    Patent number: 11208437
    Abstract: The present disclosure relates generally to bacterial delivery vehicles for use in efficient transfer of a desired payload into a target bacterial cell. More specifically, the present disclosure relates to bacterial delivery vehicles with desired host ranges based on the presence of a chimeric receptor binding protein (RBP) composed of a fusion between the N-terminal region of a RBP derived from a lambda-like bacteriophage and the C-terminal region of a different RBP, and/or the presence of an engineered branched receptor binding multi-subunit polypeptides (“branched-RBP”).
    Type: Grant
    Filed: December 23, 2019
    Date of Patent: December 28, 2021
    Assignee: Eligo Bioscience
    Inventor: Jesus Fernandez Rodriguez
  • Modified dystrophin proteins
    Patent number: 11202840
    Abstract: Synthetic nucleic acids encoding mini and microdystrophin genes comprising the membrane binding motifs or domains of the R10-R11-R12 region are provided. Also provided are vectors, host cells, and related methods of using the same to treat a subject suffering from Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD) or X-linked dilated cardiomyopathy (XLDC), or for ameliorating one or more adverse effects of DMD, BMD, or XLDC. Also provided are a fusion protein comprising a nNOS binding domain of dystrophin R16-R17 that is operably linked to a syntrophin PDZ domain and synthetic nucleic acids comprising the same that can be used to treat subjects with diseases characterized by loss of sarcolemmal neuronal nitric oxide synthase (nNOS) activity.
    Type: Grant
    Filed: June 21, 2017
    Date of Patent: December 21, 2021
    Assignee: The Curators of the University of Missouri
    Inventors: Dongsheng Duan, Yi Lai, Junling Zhao, Yongping Yue
  • Immunologic effector cell of targeted CLD18A2, and preparation method and use thereof
    Patent number: 11198729
    Abstract: Disclosed are a chimeric antigen receptor (CAR) targeting CLD18A2, and preparation method and use thereof. The extracellular binding region of the CAR comprises a protein specifically recognizing CLD18A2. The immune effector cell modified by the CAR can be used to treat tumors such as pancreatic cancer and stomach cancer.
    Type: Grant
    Filed: June 21, 2019
    Date of Patent: December 14, 2021
    Assignee: Cafa Therapeutics Limited
    Inventors: Huamao Wang, Bo Song, Xiumei Cai
  • Lipid nanoparticle compositions and methods for mRNA delivery
    Patent number: 11185595
    Abstract: Disclosed herein are compositions and methods for modulating the production of a protein in a target cell. The compositions and methods disclosed herein are capable of ameliorating diseases associated with protein or enzyme deficiencies.
    Type: Grant
    Filed: June 7, 2021
    Date of Patent: November 30, 2021
    Assignee: Translate Bio, Inc.
    Inventors: Braydon Charles Guild, Frank DeRosa, Michael Heartlein
  • Methods of enhancing female fertility
    Patent number: 11179423
    Abstract: Methods of enhancing fertility of a female subject by increasing the number of oogonia present in the ovary of the female subject are provided. Aspects of the methods include methods of in vivo expansion of oogonia as well as methods of ex vivo expansion of oogonia.
    Type: Grant
    Filed: May 10, 2018
    Date of Patent: November 23, 2021
    Assignee: Palo Alto Investors
    Inventors: Anthony Joonkyoo Yun, Conrad Minkyoo Yun, Kimberly A. Bazar
  • Restimulation of cryopreserved tumor infiltrating lymphocytes
    Patent number: 11179419
    Abstract: The present disclosure provides methods for re-stimulating TIL populations that lead to improved phenotype and increased metabolic health of the TILs and provides methods of assaying for TIL populations to determine suitability for more efficacious infusion after re-stimulation.
    Type: Grant
    Filed: April 16, 2021
    Date of Patent: November 23, 2021
    Assignee: Iovance Biotherapeutics, Inc.
    Inventors: Ian Frank, Michael T. Lotze
  • Reporter system for detecting and targeting activated cells
    Patent number: 11174495
    Abstract: The present invention provides methods and compositions for labeling and/or targeting cells with increased calcium by providing a CREB reporter system. In addition, methods of treating disorders with activated cells such as brain disorders or cancer are also provided herein.
    Type: Grant
    Filed: December 5, 2016
    Date of Patent: November 16, 2021
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventor: Boris Zemelman
  • Generation of antigen-specific TCRs
    Patent number: 11155589
    Abstract: The present invention contemplates methods for the generation of human antigen-specific T lymphocytes. The methods employ MHC class-II targeting signals fused to an antigen or fragment thereof to obtain MHC class presentation of RNA coded proteins. Accordingly, the present invention concerns expression vectors comprising MHC class-II targeting signal and at least one antigen or fragment thereof and its use for the in vitro generation of antigen-specific T lymphocytes. T cell clones and T cell receptors (TCRs) specific for tumor antigens or viral antigens are also described.
    Type: Grant
    Filed: December 22, 2016
    Date of Patent: October 26, 2021
    Assignees: Medigene Immunotherapies GmbH, Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)
    Inventors: Slavoljub Milosevic, Christian Ellinger, Carina Wehner, Dolores Schendel
  • Prokaryotic-eukaryotic hybrid viral vector for delivery of large cargos of genes and proteins into human cells
    Patent number: 11155835
    Abstract: Described is hybrid viral vector comprising: a first virus such as bacteriophage T4; one or more second virus such as adeno-associated virus (AAV) attached to the first virus through cross-bridges, such as avidin-biotin cross-bridges; one or more DNA molecules packaged in the first virus; one or more nucleic acid molecules packaged in the second virus; and one or more proteins displayed on the surface of the first virus. Also described are methods of making and using such a hybrid viral vector.
    Type: Grant
    Filed: August 11, 2020
    Date of Patent: October 26, 2021
    Assignee: The Catholic University of America
    Inventors: Venigalla B. Rao, Jingen Zhu
  • Compositions and methods for treating CEP290-associated disease
    Patent number: 11141493
    Abstract: Compositions and methods for treatment of CEP290 related diseases are disclosed.
    Type: Grant
    Filed: August 2, 2018
    Date of Patent: October 12, 2021
    Assignee: EDITAS MEDICINE, INC.
    Inventors: Morgan Lee Maeder, Rina J. Mepani, David A. Bumcrot, Shen Shen, Michael Stefanidakis
  • Restimulation of cryopreserved tumor infiltrating lymphocytes
    Patent number: 11141438
    Abstract: The present disclosure provides methods for re-stimulating TIL populations that lead to improved phenotype and increased metabolic health of the TILs and provides methods of assaying for TIL populations to determine suitability for more efficacious infusion after re-stimulation.
    Type: Grant
    Filed: April 16, 2021
    Date of Patent: October 12, 2021
    Assignee: Iovance Biotherapeutics, Inc.
    Inventors: Ian Frank, Michael T. Lotze
  • High throughput assay for measuring adenovirus replication kinetics
    Patent number: 11130968
    Abstract: Recombinant adenovirus genomes that include a heterologous open reading frame (ORF) and a self-cleaving peptide coding sequence are described. The recombinant adenovirus genomes and recombinant adenoviruses produced by the disclosed genomes can be used, for example, in high-throughput assays to measure virus replication kinetics. Methods for measuring replication kinetics of a recombinant adenovirus are also described.
    Type: Grant
    Filed: August 22, 2018
    Date of Patent: September 28, 2021
    Assignee: Salk Institute for Biological Studies
    Inventors: Clodagh O'Shea, William Partlo, Colin Powers
  • Methods of preparing and using novel stem cell compositions and kits comprising the same
    Patent number: 11129855
    Abstract: The present invention provides novel stem cell compositions having significant therapeutic and practical advantages, as well as methods of preparing and using such compositions for the treatment and prevention of injury and disease in patients. The invention may be applied to stem cell populations isolated from a wide variety of animals, including humans, and tissues. In particular applications, the invention is used to prepare a stem cell composition from a collagen-based tissue, such as adipose tissue, isolated from a patient, and the stem cell composition is subsequently provided to a site of actual or potential injury in the patient. The invention further includes related kits comprising the stem cell compositions, which are remarkably stable and retain viability and efficacy during storage and shipment.
    Type: Grant
    Filed: April 27, 2020
    Date of Patent: September 28, 2021
    Assignee: VetStem Biopharma, Inc.
    Inventors: Robert J. Harman, Jr., Theodore T. Sand
  • Method of treatment
    Patent number: 11123376
    Abstract: The present disclosure relates generally to the methods of treatment of mammalian subjects by an enhanced cell-based therapeutic approach in order to facilitate tissue and neuronal repair, regeneration and/or reparation. Medicaments useful in the treatment of mammalian subjects and methods of production of the medicaments are also encompassed by the present disclosure.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: September 21, 2021
    Assignees: MONASH UNIVERSITY, HUDSON INSTITUTE OF MEDICAL RESEARCH
    Inventors: Euan Wallace, Rebecca Lim
  • Restimulation of cryopreserved tumor infiltrating lymphocytes
    Patent number: 11123371
    Abstract: The present disclosure provides methods for re-stimulating TIL populations that lead to improved phenotype and increased metabolic health of the TILs and provides methods of assaying for TIL populations to determine suitability for more efficacious infusion after restimulation.
    Type: Grant
    Filed: April 16, 2021
    Date of Patent: September 21, 2021
    Assignee: Iovance Biotherapeutics, Inc.
    Inventors: Ian Frank, Michael T. Lotze
  • Parkinson's disease model and methods
    Patent number: 11122784
    Abstract: This application provides a novel mouse model (PLA2g6 KOEx2) in which genetic deletion of the N terminus of PLA2g6 results in a loss of dopaminergic (DA) neurons in substantia nigra (SN), and development of PD-like motor deficits that can be significantly improved by L-DOPA. Based in part on experimental results demonstrated with this model, this disclosure provides genetically modified animals and genetically modified animal cells that comprise a mutant allele of PLA2g6 and in which store-operated Ca2+ entry (SOCE) is impaired and ER Ca2+ stores are depleted. This disclosure also provides methods of screening a compound for an effect on the SOCE pathway and/or ER Ca2+ by administering the compound to such a genetically modified animal or genetically modified animal cell.
    Type: Grant
    Filed: July 31, 2019
    Date of Patent: September 21, 2021
    Assignee: Boston Medical Center Corporation
    Inventor: Victoria Bolotina
  • Genetically engineered gas vesicle gene clusters, genetic circuits, vectors, prokaryotic cells, compositions, methods and systems for contrast-enhanced imaging
    Patent number: 11118210
    Abstract: Hybrid gas vesicle gene cluster (GVGC) configured for expression in a prokaryotic host are described comprising gas vesicle assembly (GVA) genes native to a GVA prokaryotic species and capable of being expressed in a functional form in the prokaryotic host, and one or more gas vesicle structural (GVS) genes native to one or more GVS prokaryotic species, at least one of the one or more GVS prokaryotic species different from the GVA prokaryotic species, and related gas vesicle reporting (GVR) genetic circuits, genetic, vectors, engineered cells, and related compositions methods and systems to produce GVs, hybrid GVGC and/or image a target site.
    Type: Grant
    Filed: July 28, 2017
    Date of Patent: September 14, 2021
    Assignee: CALIFORNIA INSTITUTE OF TECHNOLOGY
    Inventors: Raymond W. Bourdeau, Anupama Lakshmanan, Arash Farhadi, Mikhail G. Shapiro, Audrey Lee-Gosselin
  • Materials and methods for treatment of Usher syndrome type 2A and/or non-syndromic autosomal recessive retinitis pigmentosa (ARRP)
    Patent number: 11118177
    Abstract: The present application provides materials and methods for treating a patient with one or more of Usher Syndrome Type 2A and ARRP, both ex vivo and in vivo; materials and methods for editing an USH2A gene containing a guanine deletion at nucleotide position c.2299. In addition, the present application provides one or more gRNAs or sgRNAs for editing an USH2A gene containing a guanine deletion at nucleotide position c.2299; a therapeutic comprising at least one or more gRNAs or sgRNAs for editing an USH2A gene containing a guanine deletion at nucleotide position c.2299; and a therapeutic for treating a patient with one or more of Usher Syndrome Type 2A and ARRP. The present application also provides a kit for treating a patient with one or more of Usher Syndrome Type 2A and ARRP.
    Type: Grant
    Filed: June 18, 2020
    Date of Patent: September 14, 2021
    Assignees: CRISPR THERAPEUTICS AG, BAYER HEALTHCARE LLC
    Inventors: Mariacarmela Allocca, Akiko Noma, Abraham Scaria
  • Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
    Patent number: 11110166
    Abstract: The present invention is directed to a polymeric carrier cargo complex, comprising as a cargo at least one nucleic acid molecule and as a preferably non-toxic and non-immunogenic polymeric carrier disulfide-crosslinked cationic components for use as an immunostimulating agent or as an adjuvant, wherein the polymeric carrier cargo complex is administered in combination with at least one second nucleic acid molecule, which encodes a protein or peptide. The inventive polymeric carrier cargo complex administered in combination with the second nucleic acid molecule allows for both efficient transfection of nucleic acids into cells in vivo and in vitro and/or for induction of an innate and/or adaptive immune response, preferably dependent on the nucleic acid to be transported as a cargo and on the second nucleic acid molecule.
    Type: Grant
    Filed: June 18, 2019
    Date of Patent: September 7, 2021
    Assignee: CureVac AG
    Inventors: Mariola Fotin-Mleczek, Regina Heidenreich
  • Linked perfusion to continuous-flow stirred-tank reactor cell culture system
    Patent number: 11104875
    Abstract: Methods of protein production in a linked culture and production bioreactor system are provided. Such methods include a culture bioreactor (N-1 bioreactor) linked to production bioreactor (N bioreactor). More specifically, the methods include (a) culturing cells with a gene that encodes the protein of interest in a continuous perfusion culture bioreactor (N-1 bioreactor); inoculating a continuously stirred tank reactor (CSTR) production bioreactor (N bioreactor) with cells obtained from step (a); and culturing the cells in the CSTR production bioreactor under conditions that allow production of the protein of interest.
    Type: Grant
    Filed: January 25, 2017
    Date of Patent: August 31, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Gregory Walter Hiller, Matthew Paul Gagnon, Jonathan Coffman